1. Severe perinatal hypophosphatasia case with a novel mutation.
- Author
-
Yazici H, Canda E, Kalkan Ucar S, and Coker M
- Subjects
- Alkaline Phosphatase genetics, Alkaline Phosphatase therapeutic use, Female, Humans, Infant, Mutation, Pregnancy, Seizures, Hypophosphatasia diagnosis, Hypophosphatasia drug therapy, Hypophosphatasia genetics, Nephrocalcinosis
- Abstract
Hypophosphatasia (HPP) is a rare inherited disorder caused by mutations in the ALPL gene. Mineralization defect in bones and teeth, abnormal respiratory function, seizures, hypotonia, bone pain, and nephrocalcinosis can be observed. Clinical forms are usually recognized based on age at diagnosis and severity of features. We present an infant with an enlarged anterior fontanelle, soft calvarium, fractures, respiratory distress, and seizures. Biochemical analysis showed hypercalcemia, normal serum phosphate, and low serum alkaline phosphatase (ALP) levels. X-ray showed hypomineralization, fractures, and callus formations. Plasma pyridoxal 5'-phosphate (PLP) was 762 mg/L (NV : 5-50) and urine phosphoethanolamine (PEA) was 1015 mmol/L (NV : 15-341) and ALPL gene analysis showed two compound heterozygous mutations, one of which is a novel one. Early diagnosis and treatment of perinatal HPP may improve outcomes and might have a positive impact on survival., Competing Interests: None, (Sociedad Argentina de Pediatría.)
- Published
- 2022
- Full Text
- View/download PDF